Tools
Dyspareunia
Introduction
Painful sexual intercourse is a common female health problem.[1] In medical terminology, it is called dyspareunia. It is a complex disorder that often goes neglected. The prevalence of dyspareunia varies from 3 to 18% worldwide, and it can affect 10 to 28% of the population in a lifetime.[2][3] dyspareunia can be further categorized into superficial or deep, and primary or secondary. Superficial dyspareunia is limited to the vulva or vaginal entrance, while deep dyspareunia means the extension of pain into the deeper parts of the vagina or lower pelvis. Deep dyspareunia is frequently associated with deep penetration.[4] Primary dyspareunia pain initiates at the start of sexual intercourse, while in secondary dyspareunia, pain begins after some time of pain-free sexual activity.
Dyspareunia is sometimes intermixed with vulvodynia, a genital pain that lasts more than three months with or without the association of sexual intercourse.[5] Dyspareunia can also lead to sexual difficulties, such as lack of sexual desire and arousal, and can cause trouble in sexual relationships.[6] It can have a significant impact on physical as well as mental health. It can lead to depression, anxiety, hypervigilance to pain, negative body image, and low self-esteem. So prompt management is crucial to address this disorder.[7][8][9]
In this review, we will focus on the etiology, epidemiology, evaluation, management, and prognosis of dyspareunia.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The etiology of dyspareunia encompasses structural, inflammatory, infectious, neoplastic, traumatic, hormonal, and psychosocial conditions. Anatomic causes include pelvis floor muscle dysfunction, uterine retroversion, hymenal remnants, and pelvic organ prolapse. Lack of lubrication is most common in reproductive years and is attributable to hormonal as well as sexual arousal disorders. For reproductive-aged females, contraceptives can cause inadequate lubrication. Whereas, the decreased estrogen levels noted in post-menopausal females can cause vaginal atrophy by thinning the vaginal mucosa that is responsible for promoting vaginal secretions. Endometriosis is a condition in which endometrial glands and stroma are present outside the uterus.
The etiology of endometriosis-associated deep dyspareunia could also be due to endometriosis-specific factors or indirect contributors like bladder/pelvic floor dysfunction. In women regardless of the staging of endometriosis, the severity of deep dyspareunia was strongly associated with bladder/pelvic floor tenderness and painful bladder syndrome, independent of endometriosis-specific factors, which suggests the role of myofascial or sensitization pain mechanisms in some women with deep dyspareunia.[10]
Dermatologic diseases such as lichen planus, lichen sclerosis, and psoriasis can cause significant inflammation to the vaginal mucosa as well. Perivaginal and pelvic infections such as urethritis, vaginitis, and pelvic inflammatory disease can result from gonorrhea, chlamydia, candida, trichomoniasis, bacterial vaginosis, and virals pathogens such as herpes. Postpartum dyspareunia more commonly presents after perineal trauma from delivery than those with an uncomplicated vaginal delivery with intact perineum or unsutured tear.[11]
Vaginismus is a more common condition in younger women and defined as an involuntary contraction of the pelvic floor muscles on attempted vaginal penetration and can be the result of a pelvic floor dysfunction or psychosocial issues such as a history of sexual abuse.[12]
Epidemiology
The incidence of dyspareunia mainly depends on the definition used and, therefore, the population sampled. In the United States, the prevalence can be between 7% to 46%. Dyspareunia affects both males and females. However, it is far more common in the female population. Women with symptoms severe enough to require medical attention comprise a small subset as most patients do not seek medical attention making the true incidence rather challenging to determine.[12]
History and Physical
Obtaining a history in a nonjudgmental way is crucial and should include pain descriptors: duration, intensity, location, exacerbating and alleviating factors, and any associated psychologic components. The location and onset can help to differentiate entry versus deep pain. Whereas a burning pain more commonly links to vaginitis, vulvodynia, atrophy, or inadequate lubrication, a deep aching pain may be noted in pelvic congestion syndrome, pelvic inflammatory disease, endometriosis, retroverted uterus, uterine fibroids, and adnexal pathology. A situational versus a more generalized description (occurs only with certain partners or with all encounters) may more strongly link with psychologic considerations.[13] The IMPACT( Initial Measurement of Patient-Reported Pelvic Floor Complaints Tool) form consists of different questions relevant to pelvic floor abnormalities. It also helps in dealing with dyspareunia patients.[14]
In the first step of physical examination, it is always advisable to educate the patient about the examination and her anatomy in detail.[15] Then it should begin with a visual inspection of the labia majora and labia minora, vestibular area, anus, and urethral orifice to evaluate for any lesions, labial hypertrophy, leukoplakia, or erythema. The speculum exam should take place after selecting an appropriately sized speculum (consider a pediatric speculum for patient comfort) that is warmed and lubricated. Examine the cervix for any associated lesions, erythema, and discharge at which time appropriate cultures are obtainable. The bimanual examination should then evaluate for any adnexal masses/cysts, uterine masses, and additional anatomic variants.[16][17][18]
Evaluation
Laboratory evaluation rarely helps in guiding the diagnosis or treatment of dyspareunia. However, It is better to rule out other abnormalities to reach the exact diagnosis. Since the pain in the vulvodynia is similar to dyspareunia, it is better to rule this out by performing a cotton swab test during the vulvar examination.[15]
Further tests can include pelvic cultures for gonorrhea, chlamydia, trichomoniasis, Candida, and Gardnerella are indicated when women present with vaginal or cervical discharge. Genital ulcers can be testing performed for herpes simplex, syphilis, or appropriate culture. Women with associated dysuria, urgency, frequency or suprapubic discomfort should receive a urinalysis. Visible lesions noted on physical exam should undergo tissue biopsy.[19] Transvaginal ultrasound can help evaluate pelvic masses, endometrial hyperplasia, ovarian cysts, or congenital anomalies.
Treatment / Management
For the treatment of dyspareunia, a multimodal treatment approach is advantageous to address all the aspects of pain (physical, emotional, and behavioral). It should involve a team consisting of the gynecologist, pain management expert, physical therapist, sexual therapist, and mental health professionals with a specialization in chronic pain.[20] In the first step, a physician should acknowledge that patient has pain. The patient should receive counsel that pain management may take time, and its quite possible that it may not completely resolve even after the completion of treatment. Patients should be informed of all the treatment options in detail and help them to choose the best possible treatment option. The conservative nonsurgical approach should be the first step.(B3)
Medical treatment options available for dyspareunia include oral tricyclic antidepressants, oral or topical hormonal replacement, oral NSAIDs, botox injections, cognitive behavioral therapy, and other brain-based therapies. Treatment of dyspareunia depends on the etiology of the patient's complaint. Dyspareunia due to post-menopausal vaginal atrophy can have treatment with systemic and topical hormone replacement therapy, selective estrogen receptor modulator therapy, and the use of vaginal dehydroepiandrosterone.[21] Clinicians treat infectious causes with the appropriate antibiotic, antifungal, or antiviral therapy based upon culture results. Post-partum dyspareunia can respond to vaginal lubricants, scar tissue massage, or surgery for persistent cases. Botulinum toxin injection has proved to be effective in the treatment of dyspareunia caused by pelvic floor myalgia and contracture.[22][23] (B2)
Pelvic floor physical therapy can serve as an adjuvant treatment option in most cases of dyspareunia. It relaxes the pelvic floor muscles and re-educates the pain receptors.[24] Cognitive-behavioral therapy has shown promising results in reducing anxiety and fear related to dyspareunia. It is the most commonly used behavioral intervention and is a strong recommendation.[25] Surgical treatment is adopted as a last resort when all conservative medical and behavioral treatment options have failed. It is usually useful in identifying and/or treat pelvic adhesions, endometriosis, and pelvic organ prolapse.[26]
Differential Diagnosis
To reach the exact diagnosis of dyspareunia is a tricky one as it can be confused with other disorders of similar complaints. Several disorders must be ruled out based upon the history and physical examination before making the diagnosis of dyspareunia. Some of these are listed below:
- Vulvodynia
- Vaginismus
- Atrophic vaginitis
- Vulvar vestibulitis
- Endometriosis and pelvic adhesions
- Uterine fibroids
- Pelvic congestion
- Pelvic inflammatory disease, endometritis
- Other urogenital tract infections[27]
Prognosis
The prognosis of dyspareunia depends on the causative factor of this pain. If the underlying cause is known and curable, then it has a better prognosis. Its prognosis is poor in idiopathic dyspareunia. Following treatment, patients with dyspareunia should receive counsel about the prognosis of the disorder. Treatment can last for several months, and complete resolution is also not guaranteed. Studies suggest that results start appearing after at least three months. After that, the patient's distress starts decreasing with improved quality of life. A 24-month follow-up is recommended for the best results.[28]
Complications
Dyspareunia is usually a treatable disease and doesn't result in major complications. Regardless of the non-malignant nature of the disease, timely management and intervention are crucial to obviate distressing sequelae. If the patients do not seek prompt, appropriate medical care, it can result in loss of sexual interest and problems with relationships. It also results in significant distress and conflicts among the partners.
Psychiatric issues may arise if dyspareunia remains untreated. Psychiatric issues like major depression due to dyspareunia are more prevalent in younger women. In very few cases, fear of pain during sexual activity can result in female infertility.[29]
Deterrence and Patient Education
In general, patients are hesitant to discuss their sexual dysfunctions and can go unnoticed for a long time.[30] Patients should be encouraged to discuss their sexual health with a physician. Dyspareunia is a challenging topic for discussion for both the patient and the physician. It can also lead to suboptimal management.
Clinicians need sufficient education and training to evaluate and treat the patient's dyspareunia properly.[30] It is important to allay patient fears and provide reassurance for them to discuss this condition with their primary care physician, who can then refer to specialists to guide treatment depending on the etiology.
Enhancing Healthcare Team Outcomes
Management of Dyspareunia is a typical example for healthcare providers to ensure patient-centered care. The symptoms, physical findings, and concerns related to dyspareunia are managed by collaborative efforts of a team consisting of gynecologists, urologists, psychiatrists, pain specialists, and paramedical staff. To standardize treatment, a Pelvic Floor Disorder Consortium (PFDC) came into existence, which also provides guidance to treat several other conditions. It reviews multiple symptoms, function, and quality of life questionnaires. The PFDC is comprised of urogynecologists, urologists, gynecologists, physiotherapists, and other advanced care physicians that deal with complex concerns of sexual dysfunctions.[31]
A multidisciplinary treatment approach has shown to be beneficial in dyspareunia. The general care physician usually initiates the connection with the patient and develop a rapport. Adequate education regarding the course of the disease should be provided to the patients. A psychiatrist should be involved to relieve the patient's distress. Sexual pain specialists should also offer consultation when needed. Pelvic floor rehabilitation has shown promising results in dyspareunia treatment.[32] Hence by a team effort, health care outcomes can be improved significantly.
References
Binik YM. Should dyspareunia be retained as a sexual dysfunction in DSM-V? A painful classification decision. Archives of sexual behavior. 2005 Feb:34(1):11-21 [PubMed PMID: 15772767]
Weijmar Schultz W, Basson R, Binik Y, Eschenbach D, Wesselmann U, Van Lankveld J. Women's sexual pain and its management. The journal of sexual medicine. 2005 May:2(3):301-16 [PubMed PMID: 16422861]
Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. American journal of obstetrics and gynecology. 2014 Jan:210(1):40.e1-8. doi: 10.1016/j.ajog.2013.09.033. Epub 2013 Sep 28 [PubMed PMID: 24080300]
MacNeill C. Dyspareunia. Obstetrics and gynecology clinics of North America. 2006 Dec:33(4):565-77, viii [PubMed PMID: 17116501]
Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolnoun D, Coady D, consensus vulvar pain terminology committee of the International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Women's Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS). 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstetrics and gynecology. 2016 Apr:127(4):745-751. doi: 10.1097/AOG.0000000000001359. Epub [PubMed PMID: 27008217]
Level 3 (low-level) evidenceDesrochers G, Bergeron S, Landry T, Jodoin M. Do psychosexual factors play a role in the etiology of provoked vestibulodynia? A critical review. Journal of sex & marital therapy. 2008:34(3):198-226. doi: 10.1080/00926230701866083. Epub [PubMed PMID: 18398760]
Pazmany E, Bergeron S, Van Oudenhove L, Verhaeghe J, Enzlin P. Aspects of sexual self-schema in premenopausal women with dyspareunia: associations with pain, sexual function, and sexual distress. The journal of sexual medicine. 2013 Sep:10(9):2255-64. doi: 10.1111/jsm.12237. Epub 2013 Jul 11 [PubMed PMID: 23845053]
Level 2 (mid-level) evidencePayne KA, Binik YM, Amsel R, Khalifé S. When sex hurts, anxiety and fear orient attention towards pain. European journal of pain (London, England). 2005 Aug:9(4):427-36 [PubMed PMID: 15979023]
Aikens JE, Reed BD, Gorenflo DW, Haefner HK. Depressive symptoms among women with vulvar dysesthesia. American journal of obstetrics and gynecology. 2003 Aug:189(2):462-6 [PubMed PMID: 14520219]
Level 2 (mid-level) evidenceOrr NL, Noga H, Williams C, Allaire C, Bedaiwy MA, Lisonkova S, Smith KB, Yong PJ. Deep Dyspareunia in Endometriosis: Role of the Bladder and Pelvic Floor. The journal of sexual medicine. 2018 Aug:15(8):1158-1166. doi: 10.1016/j.jsxm.2018.06.007. Epub [PubMed PMID: 30078464]
McDonald EA, Gartland D, Small R, Brown SJ. Dyspareunia and childbirth: a prospective cohort study. BJOG : an international journal of obstetrics and gynaecology. 2015 Apr:122(5):672-9. doi: 10.1111/1471-0528.13263. Epub 2015 Jan 21 [PubMed PMID: 25605464]
Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. American family physician. 2014 Oct 1:90(7):465-70 [PubMed PMID: 25369624]
Heim LJ. Evaluation and differential diagnosis of dyspareunia. American family physician. 2001 Apr 15:63(8):1535-44 [PubMed PMID: 11327429]
Bordeianou LG, Anger JT, Boutros M, Birnbaum E, Carmichael JC, Connell KA, De EJB, Mellgren A, Staller K, Vogler SA, Weinstein MM, Yafi FA, Hull TL, MEMBERS OF THE PELVIC FLOOR DISORDERS CONSORTIUM WORKING GROUPS ON PATIENT-REPORTED OUTCOMES. Measuring Pelvic Floor Disorder Symptoms Using Patient-Reported Instruments: Proceedings of the Consensus Meeting of the Pelvic Floor Consortium of the American Society of Colon and Rectal Surgeons, the International Continence Society, the American Urogynecologic Society, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction. Diseases of the colon and rectum. 2020 Jan:63(1):6-23. doi: 10.1097/DCR.0000000000001529. Epub [PubMed PMID: 31804265]
Level 3 (low-level) evidenceGoldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and Treatment. The journal of sexual medicine. 2016 Apr:13(4):572-90. doi: 10.1016/j.jsxm.2016.01.020. Epub 2016 Mar 25 [PubMed PMID: 27045258]
Braksmajer A. Struggles for medical legitimacy among women experiencing sexual pain: A qualitative study. Women & health. 2018 Apr:58(4):419-433. doi: 10.1080/03630242.2017.1306606. Epub 2017 Apr 7 [PubMed PMID: 28296628]
Level 2 (mid-level) evidenceFlynn KE, Carter J, Lin L, Lindau ST, Jeffery DD, Reese JB, Schlosser BJ, Weinfurt KP. Assessment of vulvar discomfort with sexual activity among women in the United States. American journal of obstetrics and gynecology. 2017 Apr:216(4):391.e1-391.e8. doi: 10.1016/j.ajog.2016.12.006. Epub 2016 Dec 14 [PubMed PMID: 27988269]
Larsen SB, Kragstrup J. Experiences of the first pelvic examination in a random samples of Danish teenagers. Acta obstetricia et gynecologica Scandinavica. 1995 Feb:74(2):137-41 [PubMed PMID: 7900510]
Level 2 (mid-level) evidenceSorensen J, Bautista KE, Lamvu G, Feranec J. Evaluation and Treatment of Female Sexual Pain: A Clinical Review. Cureus. 2018 Mar 27:10(3):e2379. doi: 10.7759/cureus.2379. Epub 2018 Mar 27 [PubMed PMID: 29805948]
. Committee Opinion No 673: Persistent Vulvar Pain. Obstetrics and gynecology. 2016 Sep:128(3):e78-e84. doi: 10.1097/AOG.0000000000001645. Epub [PubMed PMID: 27548558]
Level 3 (low-level) evidenceNaumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. International journal of women's health. 2018:10():387-395. doi: 10.2147/IJWH.S158913. Epub 2018 Jul 31 [PubMed PMID: 30104904]
Park AJ, Paraiso MFR. Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstetrics and gynecology. 2009 Aug:114(2 Pt 2):484-487. doi: 10.1097/AOG.0b013e3181998ce1. Epub [PubMed PMID: 19622971]
Level 3 (low-level) evidencePelletier F, Girardin M, Humbert P, Puyraveau M, Aubin F, Parratte B. Long-term assessment of effectiveness and quality of life of OnabotulinumtoxinA injections in provoked vestibulodynia. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016 Jan:30(1):106-11. doi: 10.1111/jdv.13437. Epub 2015 Oct 22 [PubMed PMID: 26491951]
Level 2 (mid-level) evidenceRosenbaum TY. Physiotherapy treatment of sexual pain disorders. Journal of sex & marital therapy. 2005 Jul-Sep:31(4):329-40 [PubMed PMID: 16020150]
Engman M, Wijma K, Wijma B. Long-term coital behaviour in women treated with cognitive behaviour therapy for superficial coital pain and vaginismus. Cognitive behaviour therapy. 2010:39(3):193-202. doi: 10.1080/16506070903571014. Epub [PubMed PMID: 20390584]
Kliethermes CJ, Shah M, Hoffstetter S, Gavard JA, Steele A. Effect of Vestibulectomy for Intractable Vulvodynia. Journal of minimally invasive gynecology. 2016 Nov-Dec:23(7):1152-1157. doi: 10.1016/j.jmig.2016.08.822. Epub 2016 Aug 25 [PubMed PMID: 27568225]
Pagano R. Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. The Australian & New Zealand journal of obstetrics & gynaecology. 1999 Feb:39(1):79-83 [PubMed PMID: 10099756]
Caruso S, Iraci M, Cianci S, Vitale SG, Fava V, Cianci A. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. Journal of pain research. 2019:12():2371-2378. doi: 10.2147/JPR.S207599. Epub 2019 Jul 29 [PubMed PMID: 31536046]
Level 2 (mid-level) evidenceYong PJ, Williams C, Bodmer-Roy S, Ezeigwe C, Zhu S, Arion K, Ambacher K, Yosef A, Wong F, Noga H, Britnell S, Yager H, Bedaiwy MA, Brotto LA, Albert AY, Lisonkova S, Allaire C. Prospective Cohort of Deep Dyspareunia in an Interdisciplinary Setting. The journal of sexual medicine. 2018 Dec:15(12):1765-1775. doi: 10.1016/j.jsxm.2018.10.005. Epub 2018 Nov 13 [PubMed PMID: 30446474]
Witzeman K, Antunez Flores O, Renzelli-Cain RI, Worly B, Moulder JK, Carrillo JF, Schneider B. Patient-Physician Interactions Regarding Dyspareunia with Endometriosis: Online Survey Results. Journal of pain research. 2020:13():1579-1589. doi: 10.2147/JPR.S248887. Epub 2020 Jun 29 [PubMed PMID: 32636669]
Level 3 (low-level) evidenceGrimes WR, Stratton M. Pelvic Floor Dysfunction. StatPearls. 2023 Jan:(): [PubMed PMID: 32644672]
Ghaderi F, Bastani P, Hajebrahimi S, Jafarabadi MA, Berghmans B. Pelvic floor rehabilitation in the treatment of women with dyspareunia: a randomized controlled clinical trial. International urogynecology journal. 2019 Nov:30(11):1849-1855. doi: 10.1007/s00192-019-04019-3. Epub 2019 Jul 8 [PubMed PMID: 31286158]
Level 1 (high-level) evidence